ABBVIE INC.
ABBV Real Time Price USD$ABBV stock is featured in our Rob Bresnahan, Tom Carper, and Dan Meuser strategies.
All StrategiesRecent trades of ABBV by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in ABBV holdings by institutional investors
Quarterly net insider trading by ABBV's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$980,000 Oct 20, 2025 Issue: Trade (domestic/foreign) Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Labor Issues/Antitrust/Workplace
-
$1,160,000 Jul 21, 2025 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Labor Issues/Antitrust/Workplace Trade (domestic/foreign)
-
$2,110,000 Apr 21, 2025 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Labor Issues/Antitrust/Workplace
-
$1,080,000 Jan 21, 2025 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Labor Issues/Antitrust/Workplace
-
$1,280,000 Oct 21, 2024 Issue: Labor Issues/Antitrust/Workplace Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$580,000 Jul 22, 2024 Issue: Labor Issues/Antitrust/Workplace Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$1,590,000 Apr 22, 2024 Issue: Labor Issues/Antitrust/Workplace Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$830,000 Jan 22, 2024 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$750,000 Oct 20, 2023 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$600,000 Jul 20, 2023 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$970,000 Jan 20, 2023 Issue: Budget/Appropriations Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$2,370,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$880,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$3,980,000 Apr 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
-
$1,290,000 Jan 20, 2022 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code
-
$1,940,000 Oct 20, 2021 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code
-
$680,000 Jul 20, 2021 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$3,090,000 Apr 20, 2021 Issue: Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark Medicare/Medicaid Trade (domestic/foreign)
-
$650,000 Jan 20, 2021 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$1,430,000 Oct 20, 2020 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$670,000 Jul 20, 2020 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark
-
$2,980,000 Apr 20, 2020 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$970,000 Jan 21, 2020 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Budget/Appropriations
-
$1,790,000 Oct 21, 2019 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark
-
$900,000 Jul 22, 2019 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$2,680,000 Apr 22, 2019 Issue: Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Health Issues
-
$1,820,000 Jan 22, 2019 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code
-
$600,000 Oct 22, 2018 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code
-
$790,000 Jul 20, 2018 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$2,890,000 Apr 20, 2018 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$1,280,000 Jan 22, 2018 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Disaster Planning/Emergencies
-
$1,200,000 Oct 20, 2017 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$720,000 Jul 20, 2017 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark Budget/Appropriations
-
$2,460,000 Apr 20, 2017 Issue: Medicare/Medicaid Health Issues Trade (domestic/foreign) Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark
-
$1,040,000 Jan 20, 2017 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$2,610,000 Oct 28, 2016 Issue: Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid Budget/Appropriations
-
$1,920,000 Oct 20, 2016 Issue: Budget/Appropriations Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Medicare/Medicaid
-
$1,700,000 Jul 20, 2016 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Budget/Appropriations
-
$1,180,000 Jan 20, 2016 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$1,240,000 Oct 19, 2015 Issue: Health Issues Taxation/Internal Revenue Code Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign)
-
$930,000 Oct 19, 2015 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark Trade (domestic/foreign)
-
$1,870,000 Oct 19, 2015 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Budget/Appropriations Trade (domestic/foreign)
-
$1,010,000 Jan 20, 2015 Issue: Budget/Appropriations Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid
-
$1,600,000 Oct 17, 2014 Issue: Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid Budget/Appropriations Trade (domestic/foreign)
-
$880,000 Jul 21, 2014 Issue: Budget/Appropriations Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid Copyright/Patent/Trademark
-
$1,450,000 Apr 21, 2014 Issue: Budget/Appropriations Health Issues Medicare/Medicaid Trade (domestic/foreign) Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$600,000 Jan 21, 2014 Issue: Trade (domestic/foreign) Health Issues Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$630,000 Oct 21, 2013 Issue: Science/Technology Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid Budget/Appropriations Health Issues
-
$1,180,000 Oct 21, 2013 Issue: Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Budget/Appropriations Medicare/Medicaid
-
$770,000 Apr 22, 2013 Issue: Health Issues Budget/Appropriations Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid
ABBV Estimated quarterly lobbying spending
ABBV Revenue by Segment or Geography
New ABBV patent grants
-
Patent Title: Single-chain trail-receptor agonist proteins Mar. 06, 2018
-
Patent Title: Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Jan. 30, 2018
-
Patent Title: Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl and solid state forms thereof Jan. 30, 2018
-
Patent Title: Indazolones as modulators of tnf signaling Jan. 30, 2018
-
Patent Title: Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases Jan. 30, 2018
-
Patent Title: Salt and crystalline forms thereof of a drug Jan. 23, 2018
-
Patent Title: Methods of treatment using selective bcl-2 inhibitors Jan. 23, 2018
-
Patent Title: Monovalent binding proteins Jan. 02, 2018
-
Patent Title: 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof Jan. 02, 2018
-
Patent Title: Tricyclic modulators of tnf signaling Jan. 02, 2018
-
Patent Title: Methods for improving lipid profiles using atrasentan Jan. 02, 2018
-
Patent Title: Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Dec. 19, 2017
-
Patent Title: Antibodies against platelet-derived growth factor (pdgf) Dec. 12, 2017
-
Patent Title: Salts and crystalline forms of an apoptosis-inducing agent Dec. 12, 2017
-
Patent Title: Anti-egfr antibodies and antibody drug conjugates Nov. 28, 2017
-
Patent Title: Application security framework Nov. 21, 2017
-
Patent Title: Synthetic route to anti-viral agents Nov. 07, 2017
-
Patent Title: Difluoroalkylcyclopropyl amino acids and esters, and syntheses thereof Nov. 07, 2017
-
Patent Title: Immunobinders directed against tnf Oct. 31, 2017
-
Patent Title: Process for preparing antiviral compound Oct. 31, 2017
-
Patent Title: Pyrrolo [2,3-b] pyridine cdk9 kinase inhibitors Oct. 24, 2017
-
Patent Title: Inhibitor compounds of phosphodiesterase type 10a Oct. 17, 2017
-
Patent Title: Indazole ureas and method of use Oct. 10, 2017
-
Patent Title: Furo-3-carboxamide derivatives and methods of use Oct. 03, 2017
-
Patent Title: Isoindolone derivatives Oct. 03, 2017
-
Patent Title: Nampt inhibitors Sep. 12, 2017
-
Patent Title: Characterization and/or detection of structural characteristics associated with syringes and/or automatic injection devices based on acoustics Sep. 05, 2017
-
Patent Title: Trpa1 antagonists Sep. 05, 2017
-
Patent Title: Solid antiviral dosage forms Aug. 29, 2017
-
Patent Title: Process for preparing antiviral compounds Aug. 15, 2017
-
Patent Title: Prolactin receptor binding proteins and uses thereof Aug. 08, 2017
-
Patent Title: Pyridopyrimidinone inhibitors of kinases Aug. 01, 2017
-
Patent Title: Methods to modulate lysine variant distribution Jul. 18, 2017
-
Patent Title: Protein purification using displacement chromatography Jul. 18, 2017
-
Patent Title: Low acidic species compositions and methods for producing and using the same using displacement chromatography Jun. 27, 2017
-
Patent Title: Molecules that are able to inhibit the binding between ngf and the trka receptor as analgesics with prolonged effect Jun. 27, 2017
-
Patent Title: Cell culture methods to reduce acidic species Jun. 20, 2017
-
Patent Title: (indazol-4-yl) hexahydropyrrolopyrrolones and methods of use Jun. 20, 2017
-
Patent Title: Anti-viral compounds Jun. 13, 2017
-
Patent Title: Il-1 binding proteins Jun. 06, 2017
-
Patent Title: Phosphine ligands for catalytic reactions Jun. 06, 2017
-
Patent Title: Syringe with two-stage sealing pressure Jun. 06, 2017
-
Patent Title: Il-17 binding proteins May. 30, 2017
-
Patent Title: Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy May. 23, 2017
-
Patent Title: Bispecific antibodies directed against tnf-α and il-17 May. 23, 2017
-
Patent Title: Pyridine cdk9 kinase inhibitors May. 16, 2017
-
Patent Title: Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy May. 16, 2017
-
Patent Title: Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor May. 09, 2017
-
Patent Title: Antiviral compounds and uses thereof May. 02, 2017
-
Patent Title: Atrasentan mandelate salts May. 02, 2017
Federal grants, loans, and purchases
- $21,573 2025-11-21 00:00:00 Agency: Department of Veterans Affairs
- $51,844 2025-11-14 00:00:00 Agency: Department of Health and Human Services
- $113,265 2025-10-01 00:00:00 Agency: Department of Veterans Affairs
- $164,749 2025-10-01 00:00:00 Agency: Department of Veterans Affairs
- $0 2025-07-28 00:00:00 Agency: Department of Veterans Affairs
- $0 2025-06-24 00:00:00 Agency: Department of Veterans Affairs
- $21,839 2025-05-12 00:00:00 Agency: Department of Veterans Affairs
- $6,865 2025-05-07 00:00:00 Agency: Department of Veterans Affairs
- $61,781 2025-04-16 00:00:00 Agency: Department of Veterans Affairs
- $21,869 2025-04-15 00:00:00 Agency: Department of Veterans Affairs
- $42,028 2025-02-06 00:00:00 Agency: Department of Veterans Affairs
- $47,085 2025-01-22 00:00:00 Agency: Department of Veterans Affairs
- $49,850 2024-11-21 00:00:00 Agency: Department of Health and Human Services
- $0 2024-11-12 00:00:00 Agency: Department of Veterans Affairs
- $14,355 2024-08-19 00:00:00 Agency: Department of Veterans Affairs
- $47,933 2023-12-20 00:00:00 Agency: Department of Health and Human Services
- $0 2023-12-13 00:00:00 Agency: Department of Health and Human Services
- $14,913 2023-10-10 00:00:00 Agency: Department of Veterans Affairs
- $0 2023-09-28 00:00:00 Agency: Department of Veterans Affairs
- $14,913 2023-09-22 00:00:00 Agency: Department of Veterans Affairs
- $25,528 2023-08-12 00:00:00 Agency: Department of Veterans Affairs
- $16,200 2023-08-01 00:00:00 Agency: Department of Veterans Affairs
- $21,600 2023-04-03 00:00:00 Agency: Department of Veterans Affairs
- $8,408 2021-09-22 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $12,891 2021-01-19 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Estimated quarterly amount awarded to ABBV from public contracts
Recent insights relating to ABBV
Recent picks made for ABBV stock on CNBC
ETFs with the largest estimated holdings in ABBV
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ABBV stock a Buy, Sell, or Hold?
- What is the price target for $ABBV stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ABBV stock?
- Who owns the most shares of $ABBV stock?
- What funds own $ABBV stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ABBV Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
- Address North Chicago, IL
- Market Cap 394.7 billion
- Employees 55,000
- Industrial Classification Pharmaceutical Preparations